Experimental drugs designed to reduce the body's natural production of alpha-ketoglutarate slow tumor growth and increase lifespan in mouse models of DIPG.
A small molecular compound has been discovered that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma brain cancer, making tumors more responsive to therapies.
MP-Pt(IV), a second generation prodrug appears to have curative properties against glioblastoma when coupled with chemotherapy in mouse models.
Researchers have identified a cancer-causing mutation in the PDGFRA gene that drives cell mutation and growth when activated. The findings have implications for the treatment of a subset of glioblastoma brain cancer.
Study reports brain tumors may arise when damaged brain tissue does not heal correctly. Researchers say some glioblastoma form when the normal healing process gets derailed by mutations. This process could begin many years before patients become symptomatic of brain cancer.